29Aug 2021
Disease Flare and Reactogenicity in Patients with Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS‐CoV‐2 Messenger RNA Vaccination

Disease Flare and Reactogenicity in Patients with Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS‐CoV‐2 Messenger RNA Vaccination

We aimed to evaluate disease flare and post vaccination reactions in patients with rheumatic and musculoskeletal diseases following two dose SARS-CoV-2 mRNA vaccination. 1377 patients with RMD who received two dose SARS-CoV-2 mRNA vaccination between 16 December 2020 and April 15, 2021 completed questionnaires detailing local and systemic reactions experienced within 7 days of each vaccine dose , and one month after D2 detailing flare of RMD. Flare was associated with prior SARS-CoV-2 infection , flare in the six months preceding vaccination and use of combination immunomodulatory therapy. No allergic reactions or SARS-CoV-2 diagnoses were reported. Flare of underlying RMD following SARS-CoV-2 vaccination was uncommon.

  • #orthopaedics

Like

Save

Share